吉利德科学Gilead Sciences (GILD) 2014年年度报告「NASDAQ」.pdf

1、Gilead Annual Report 2014We made tremendous progress during the year,introducing new therapies for hepatitis C and cancer while continuing to build on achievements in HIV with regulatory filings for the companys first tenofovir alafenamide(TAF)-based single tablet regimen(STR)in the United States an

2、d the European Union.We forged new partnerships,expanded the companys geographic reach to now include operations in more than 30 countries across six continents and made strides to increase access to our medicines worldwide.The companys 2014 financial performance,with total revenues of$24.9 billion,

3、reflects an ongoing focus on scientific innovation that delivers best-in-class medications to patients with diseases that represent significant unmet needs around the world.Continued Innovation for the Treatment of Liver DiseasesHepatitis C-related liver disease poses a threat to the health of milli

4、ons of people worldwide.Sovaldi,an important therapeutic advance for the treatment of chronic hepatitis C virus(HCV),received approval in the United States and European Union in December 2013 and January 2014,respectively.Today,Sovaldi is approved in more than 40 countries,and at the end of 2014,mor

5、e than 170,000 chronic HCV patients had been treated with a Sovaldi-containing regimen since the product was first approved.In 2014,Harvoni was approved in the United States,Canada,the European Union and Switzerland.Harvoni is the first once-daily STR for the treatment of chronic HCV infection in ge

6、notype 1 patientsthe most prevalent genotype worldwide.Harvoni represents a significant medical advance in the treatment of HCV because its simple,tolerable,eliminates the need for both interferon and ribavirin,and results in high cure rates.In clinical trials of individuals with genotype 1 infectio